Legal Action Against Regencell: Investors Urged to Join Class Action for Allegedly False Statements

Regencell Investors Take Action: Join the Class Action Lawsuit

In a significant turn of events, Bronstein, Gewirtz & Grossman LLC, a leading law firm specialized in investor rights, has announced the filing of a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) and certain company officers. The lawsuit seeks to recover damages for alleged violations of federal securities laws on behalf of all individuals and entities who purchased or acquired Regencell securities between October 28, 2024, and October 31, 2025.

Background of the Case

The legal complaint claims that throughout the specified period, Regencell and its executives misled investors about the company's business and operational integrity. Key allegations include that the company faced vulnerabilities and was potentially subject to market manipulation. These issues contributed to substantial volatility in Regencell's share price, exposing investors to significant financial risks.

The lawsuit further alleges that Regencell's public statements were materially false and misleading, failing to disclose crucial information regarding regulatory scrutiny, governmental enforcement, and risks associated with their business practices. The ramifications of these misleading statements are significant, as they could lead to severe legal, monetary, and reputational damage to the company and its stakeholders.

Who Should Join the Lawsuit

Investors who acquired Regencell securities within the specified timeframe are encouraged to participate in this class action. Those affected can find additional information by visiting the law firm’s website at bgandg.com/RGC. Interested parties must act quickly as there is a deadline; specifically, they have until June 23, 2026, to seek appointment as lead plaintiff. This does not mean, however, that one must be a lead plaintiff to share in any potential recovery from the lawsuit.

No Upfront Costs for Investors

Bronstein, Gewirtz & Grossman LLC represents its clients on a contingency fee basis, indicating that there will be no cost to investors unless the firm successfully recovers funds through the lawsuit. If successful, they will request reimbursement for out-of-pocket expenses and legal fees, typically a percentage of any awarded recovery. This model ensures that all investors seeking justice can do so without financial strain.

The Firm's Credibility and Assurance

With a proven track record and national recognition, Bronstein, Gewirtz & Grossman LLC has successfully recovered hundreds of millions of dollars for investors involved in securities fraud cases across the nation. The firm’s commitment to restoring capital to investors and ensuring corporate responsibility serves to uphold marketplace integrity.

Peretz Bronstein, the founding partner of the firm, emphasized the importance of their work: “Our practice centers on restoring investor capital and ensuring corporate accountability.” Such dedication can inspire confidence in potential clients who may feel vulnerable after the loss of investments in Regencell.

Stay Updated

Investors and interested parties are encouraged to follow Bronstein, Gewirtz & Grossman on their social media channels including LinkedIn, X, Facebook, and Instagram for the latest updates regarding this class action and other investor rights news.

In conclusion, the Regencell class action lawsuit presents an opportunity for impacted investors to seek accountability and possible recovery for losses incurred during the alleged mismanagement period. By banding together, investors may enhance their chances of receiving restitution.

For queries, potential plaintiffs can reach out to Peretz Bronstein or Nathan Miller at Bronstein, Gewirtz & Grossman, LLC via phone at 917-590-0911.